Investor Presentaiton

Investor presentation Full year 2018 Slide 59 Novo Nordisk's key diabetes care products remain broadly available in the USA Value market shares of Novo Nordisk key products in the USA Share of unrestricted market access of Value market share 80% 60% 40% 20% VictozaⓇ TresibaⓇ NovoLogⓇ OzempicⓇ Novo Nordisk key products in the USA LevemirⓇ Unrestricted Market access VictozaⓇ TresibaⓇ NovoLogⓇ OzempicⓇ LevemirⓇ 100% 80% 60% 40% 0% Nov 2015 Source: IQVIA NSP Nov 2018; 20% 0% Nov 2018 Note: Market shares: NovoLog®: share of rapid acting insulin segment; LevemirⓇ: share of basal insulin segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment, Ozempic®: share of GLP-1 segment changing Jul 2015 Source: FingerTip Formulary bridge, Oct 2018 Nomenclature and Xponent PlanTrak; only considers bridged volume; excludes cash and mail order data; Note: Unrestricted access excludes prior authorisation, step edits and other restrictions LevemirⓇ access based on FlexTouch® Pen; NovoLog® access based on FlexPenⓇ; only considers bridged volume; TresibaⓇ launched in Jan 2016, OzempicⓇ launched in Feb 2018 diabetes Oct 2018 novo nordisk

View entire presentation